Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human

被引:390
作者
Shah, Dhaval K. [1 ]
Betts, Alison M. [1 ]
机构
[1] Pfizer Global Res & Dev Groton Labs, Dept Pharmacokinet Dynam & Metab, Translat Res Grp, Groton, CT 06340 USA
关键词
Monoclonal antibody; Tissue disposition; Physiologically based pharmacokinetic; Interspecies scaling; FcRn; NEONATAL FC-RECEPTOR; I-RELATED RECEPTOR; SERUM HALF-LIVES; PHARMACOKINETIC MODEL; EPITHELIAL-CELLS; IMMUNOGLOBULIN-G; RETROSPECTIVE ANALYSIS; DRUG DEVELOPMENT; DOSE ESTIMATION; IGG ANTIBODIES;
D O I
10.1007/s10928-011-9232-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objectives of the following investigation were (1) development of a physiologically based pharmacokinetic (PBPK) model capable of characterizing the plasma and tissue pharmacokinetics (PK) of nonspecific or antigen specific monoclonal antibodies (mAbs) in wild type, FcRn knockout, tumor bearing and non tumor bearing mice and (2) evaluation of the scale up potential of the model by characterizing the mouse, rat, monkey and human plasma PK of mAbs, simultaneously. A PBPK model containing 15 tissues, a carcass and a tumor compartment was developed by modifying/augmenting previously published PBPK models. Each tissue compartment was subdivided into plasma, blood cell, endothelial, interstitial and cellular sub-compartments. Each tissue was connected through blood and lymph flow to the systemic circulation. Lymph flow was set to a value 500 times lower than plasma flow and vascular reflection coefficients for each tissue were adjusted according to their vascular pore size. In each tissue endothelial space, mAb entered via pinocytosis and the interaction of FcRn with mAb was described by on and off rates. FcRn bound mAb was recycled and unbound mAb was eliminated by a first order process (K-deg). The PBPK model was simultaneously fit to the following datasets to estimate four system parameters: (1) plasma and tissue PK of nonspecific mAb in wild type mouse with or without simultaneous intravenous immunoglobulin (IVIG) administration, (2) plasma and tissue PK of nonspecific mAb in FcRn knockout mouse, (3) plasma and tissue PK of nonspecific mAb in tumor bearing mouse, (4) plasma and tissue PK of tumor antigen specific mAb in tumor bearing mouse, and (5) plasma PK of mAb in rat, monkey and human. The model was able to characterize all the datasets reasonably well with a common set of parameters. The estimated value of the four system parameters i.e. FcRn concentration (FcRn), rate of pinocytosis per unit endosomal space (CLup), K-deg and the proportionality constant (C_LNLF) between the rate at which antibody transfers from the lymph node compartment to the blood compartment and the plasma flow of the given species, were found to be 4.98E-05 M (CV% = 11.1), 3.66E-02 l/h/l (%CV = 3.48), 42.9 1/h (%CV = 15.7) and 9.1 (CV% > 50). Thus, a platform PBPK model has been developed that can not only simultaneously characterize mAb disposition data obtained from various previously published mouse PBPK models but is also capable of characterizing mAb disposition in various preclinical species and human.
引用
收藏
页码:67 / 86
页数:20
相关论文
共 70 条
[1]   Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism [J].
Akilesh, Shreeram ;
Christianson, Gregory J. ;
Roopenian, Derry C. ;
Shaw, Andrey S. .
JOURNAL OF IMMUNOLOGY, 2007, 179 (07) :4580-4588
[2]   Antibody-drug conjugates: targeted drug delivery for cancer [J].
Alley, Stephen C. ;
Okeley, Nicole M. ;
Senter, Peter D. .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2010, 14 (04) :529-537
[3]  
BAXTER LT, 1994, CANCER RES, V54, P1517
[4]  
BAXTER LT, 1995, CANCER RES, V55, P4611
[5]   Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab')(2) and fab after intravenous administration in the rat [J].
BazinRedureau, MI ;
Renard, CB ;
Scherrmann, JMG .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1997, 49 (03) :277-281
[6]   THIOPENTAL PHARMACOKINETICS [J].
BISCHOFF, KB ;
DEDRICK, RL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1968, 57 (08) :1346-&
[7]   METHOTREXATE PHARMACOKINETICS [J].
BISCHOFF, KB ;
DEDRICK, RL ;
ZAHARKO, DS ;
LONGSTRETH, JA .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1971, 60 (08) :1128-+
[8]   A MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I-RELATED FC RECEPTOR FOR IGG ON RAT HEPATOCYTES [J].
BLUMBERG, RS ;
KOSS, T ;
STORY, CM ;
BARISANI, D ;
POLISCHUK, J ;
LIPIN, A ;
PABLO, L ;
GREEN, R ;
SIMISTER, NE .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (05) :2397-2402
[9]   Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice [J].
Borvak, J ;
Richardson, J ;
Medesan, C ;
Antohe, F ;
Radu, C ;
Simionescu, M ;
Ghetie, V ;
Ward, ES .
INTERNATIONAL IMMUNOLOGY, 1998, 10 (09) :1289-1298
[10]   Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics [J].
Boswell, C. Andrew ;
Tesar, Devin B. ;
Mukhyala, Kiran ;
Theil, Frank-Peter ;
Fielder, Paul J. ;
Khawli, Leslie A. .
BIOCONJUGATE CHEMISTRY, 2010, 21 (12) :2153-2163